Business of the House

Lilian Greenwood Excerpts

Thursday 21st July 2016 Commons Chamber

[Mr Lidington]

I thank my hon. Friend for his welcome. As a Member who represents another high-growth area, I am very familiar with the issues that he has raised. Such issues need to be viewed holistically, because it is a question of looking not simply at the provision of hospital services but at the treatment of health services as a whole. Sometimes the pressures can be eased by some sensible reconfiguration of services overall, but account must be taken of the way in which medical science has moved on, and the fact that more people can now be treated as out-patients or day patients rather than having a long in-patient stay. However, I will draw my hon. Friend’s points about Kettering to the attention of the Health Secretary.

[Lilian Greenwood (Nottingham South) (Lab)]

I, too, welcome the new Leader of the House.

In 2012, my 14-year-old constituent Elly Blacknell was diagnosed with osteosarcoma, and her treatment included having her leg amputated above the knee. Recently Elly relapsed and asked to re-access Mifamurtide, a drug that she had been prescribed but could not tolerate when she was younger. Her oncologist, Professor David Walker of Nottingham Children’s Hospital, has acted as an advocate for her, but has been unable to find a way through the NHS system of funding, although Mifamurtide is the first drug to be launched specifically to deal with such tumours for 30 years. May we have a debate on the difficulties involved in introducing new drugs to treat rare tumours in children, which are so badly needed by remarkable young people like Elly?

[Mr Lidington]

For obvious reasons, I am not familiar with the case or the drug, but I will draw the hon. Lady’s remarks to the attention of the responsible Health Minister. I also suggest that this is precisely the sort of subject for which an Adjournment debate in the autumn might be suitable.